Antithrombotic and thrombolytic therapy for ischemic stroke

Chest

Volumn 114, Issue 5 SUPPL., 1998, Pages 683S-698S

  Albers, Gregory W ^a   Easton, J Donald ^a   Sacco, Ralph L ^a   Teal, Philip ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DANAPAROID; DIPYRIDAMOLE; FIBRINOLYTIC AGENT; HEPARIN; STREPTOKINASE; TICLOPIDINE; UROKINASE;

ANTICOAGULATION; CLINICAL TRIAL; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DISEASE CLASSIFICATION; DRUG EFFICACY; FIBRINOLYTIC THERAPY; HEART ATRIUM SEPTUM DEFECT; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; LUNG EMBOLISM; ORAL DRUG ADMINISTRATION; PATIENT SELECTION; PRIORITY JOURNAL; STROKE; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031787520     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.114.5_Supplement.683S     Document Type: Conference Paper

References (5)

1. Sherman DG, Dyken ML, Gent M, et al. Antithrombotic therapy for cerebrovascular disorders: an update. Chest 1995; 108:4445-456S
2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333:1581-1587
3. Australian Urokinase Stroke Trial (AUST). Major ongoing stroke trials. Stroke 1998; 29:550
4. European and Australian Cooperative Stroke Study II (ECASS-II). Major ongoing stroke trials. Stroke 1998; 29:551
5. del Zoppo GJ, Higashida RT, Furlan AJ, et al. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke 1998; 29:4-11